Sato Junko, Uchida Toyoyoshi, Komiya Koji, Goto Hiromasa, Takeno Kageumi, Suzuki Ruriko, Honda Akira, Himuro Miwa, Watada Hirotaka
Department of Metabolism & Endocrinology, Juntendo University Graduate School, Tokyo, Japan.
Endocrine. 2017 Jan;55(1):209-214. doi: 10.1007/s12020-016-1122-3. Epub 2016 Sep 29.
Subacute thyroiditis is a transient inflammatory thyroid disease of unknown etiology. The primary goal for treatment is to mitigate inflammation. The aim of this retrospective study was to compare the therapeutic effects of prednisolone and nonsteroidal anti-inflammation drugs in patients with subacute thyroiditis. In this study, 53 consecutive Japanese patients who had been diagnosed with were referred to our hospital for further management. After excluding 11 patients (9 did not need treatment, 2 did not meet the criteria for diagnosis of subacute thyroiditis), the remaining 42 patients were treated either with prednisolone (n = 25) or loxoprofen (n = 17). We compared the time periods required for resolution of clinical symptoms and signs and normalization of thyroid function between the two groups. The mean dose of prednisolone was 15.0 (range, 14-16) mg/day and that of loxoprofen was 180 mg/day. The time period to normalization of thyroid function was comparable between the prednisolone and loxoprofen groups (25, 18-36, vs 32, 21-39 days, p = 0.388). However, the time period for resolution of symptoms was shorter under prednisolone than loxoprofen (7, 7-12 days, vs 21, 14-32 days, p < 0.001). Prednisolone treatment of patients with subacute thyroiditis was superior to nonsteroidal anti-inflammation drugs with regard to resolution of symptoms.
亚急性甲状腺炎是一种病因不明的短暂性炎症性甲状腺疾病。治疗的主要目标是减轻炎症。本回顾性研究的目的是比较泼尼松龙和非甾体类抗炎药对亚急性甲状腺炎患者的治疗效果。在本研究中，53例连续诊断为亚急性甲状腺炎的日本患者被转诊至我院进行进一步治疗。排除11例患者（9例无需治疗，2例不符合亚急性甲状腺炎诊断标准）后，其余42例患者分别接受泼尼松龙治疗（n = 25）或洛索洛芬治疗（n = 17）。我们比较了两组患者临床症状和体征消退以及甲状腺功能恢复正常所需的时间。泼尼松龙的平均剂量为15.0（范围14 - 16）mg/天，洛索洛芬的平均剂量为180 mg/天。泼尼松龙组和洛索洛芬组甲状腺功能恢复正常的时间相当（分别为25天，18 - 36天，与32天，21 - 39天，p = 0.388）。然而，泼尼松龙治疗组症状消退时间比洛索洛芬组短（分别为7天，7 - 12天，与21天，14 - 32天，p < 0.001）。在症状消退方面，泼尼松龙治疗亚急性甲状腺炎患者优于非甾体类抗炎药。
